Revelation Biosciences (REVB)
(Delayed Data from NSDQ)
$2.18 USD
+0.04 (1.87%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $2.18 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Revelation Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 9 | 11 | 3 | 0 | 0 |
Income After Depreciation & Amortization | -9 | -11 | -3 | 0 | 0 |
Non-Operating Income | 9 | 0 | 1 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 0 | -11 | -2 | 0 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 0 | -11 | -2 | 0 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 0 | -11 | -2 | 0 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -9 | -11 | -3 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -9 | -11 | -3 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.23 | 0.02 | 0.00 | NA | NA |
Diluted EPS Before Non-Recurring Items | -36.96 | -603.30 | -1,228.50 | NA | NA |
Diluted Net EPS (GAAP) | -0.53 | -603.30 | -1,228.50 | -31.50 | NA |
Fiscal Year end for Revelation Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.33 | 2.78 | 1.93 | 1.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.33 | -2.78 | -1.93 | -1.62 |
Non-Operating Income | NA | 0.12 | 0.15 | 0.48 | 7.78 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -2.20 | -2.63 | -1.45 | 6.16 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.20 | -2.63 | -1.45 | 6.16 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.20 | -2.63 | -1.45 | 6.16 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 0.27 | 0.21 | 0.19 | 0.10 |
Diluted EPS Before Non-Recurring Items | NA | -8.33 | -12.31 | -7.51 | -15.32 |
Diluted Net EPS (GAAP) | NA | -39.27 | -12.61 | -7.51 | 58.86 |